SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and fibre channel storage area networking business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broadcom is actively trending ahead of its earnings report, sparking a widespread debate among investors on whether it will follow the recent "sell the news" pattern seen with other AI chip stocks, or if its robust custom silicon and AI networking demand will drive a rally. The community is closely watching its AI revenue growth and guidance, with some optimistic about its core business in data center infrastructure and others concerned about broader market sentiment and hyperscaler spending trends.

Day One Biopharmaceuticals, Inc. operates as a holding company. The firm, through its subsidiary, develops and commercializes targeted therapies for patients of all ages with genetically defined cancers. Its products include DAY101 and pimsertib. The company was founded by Julie Grant and Samuel C. Blackman in November 2018 and is headquartered in Brisbane, CA.

Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals is trending amidst strong buyout speculation and unusual options activity, fueling community discussion around a potential acquisition, even as the company reports robust commercial momentum for its lead drug OJEMDA and strategic pipeline growth.

JD.com, Inc. is a technology-driven E-commerce company, which engages in the sale of electronics products and general merchandise products, including audio, video products, and books. It operates in the following segments: JD Retail, JD Logistics, and New Businesses. The JD Retail segment offers online retail, online marketplace, and marketing services. The JD Logistics segment includes internal and external logistics businesses. The New Businesses segment is composed of JD Property, Jingxi, overseas businesses and technology initiatives. The company was founded on June 18, 1998, by Qiang Dong Liu and is headquartered in Beijing, China.

JD.com Inc - ADR

JD.com is trending as investors await its upcoming earnings report, sparking a sharp debate within the community; while many express frustration over its prolonged underperformance and consistent downward price action, others are highlighting its deeply undervalued fundamentals and substantial cash reserves as potential catalysts for a turnaround amidst broader concerns about China's e-commerce sector and geopolitical sentiment.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is experiencing significant momentum driven by a slew of new mobile network operator partnerships, including Telus becoming an equity shareholder, alongside strong analyst upgrades and solid revenue performance. The community is buzzing with short squeeze potential and high future valuation expectations for its direct-to-device satellite technology, especially given its strong relative strength in the current market.

Infinite Money Glitch ($IMG) is revolutionizing DeFi on Solana by leveraging the Token2022 program's advanced tax extension capabilities to create a truly innovative reward system for token holders.  At its core, $IMG implements a seamless 5% tax on all transactions - whether buying, selling, or transferring tokens. This tax is automatically collected and distributed to holders in SOL, creating a sustainable passive income stream for the community. 4.5% of the tax gets sent to holders, while .5% gets sent to an Infrastructure wallet to help with development, marketing and general infrastructure.  What sets $IMG apart is its implementation of Solana's Token2022 program, enabling automated and efficient reward distribution without relying on external smart contracts.

Infinite Money Glitch

Infinite Money Glitch ($IMG) is trending as its community celebrates a one-year anniversary, emphasizing consistent passive Solana rewards and new token burns designed to tighten supply.

The Walt Disney Co. engages in the business of international family entertainment and media enterprise. It owns and operates television and radio production, distribution and broadcasting stations, direct-to-consumer services, amusement parks, and hotels. It operates through the following business segments: Disney Entertainment, ESPN, and Disney Parks, Experiences, and Products. The company was founded by Walter Elias Disney on October 16, 1923 and is headquartered in Burbank, CA.

Walt Disney Co (The)

Walt Disney Co

Disney is trending following the announcement of Josh D'Amaro as the new CEO and its latest earnings report, which highlighted strong performance in parks and accelerating streaming profitability, alongside a significant share buyback program. The community is actively discussing whether the new leadership and financial results will effectively address ongoing concerns about content strategy and the stock's valuation, despite largely beating analyst expectations.

Babcock & Wilcox Enterprises, Inc. engages in the provision of fossil and renewable power generation and environmental equipment. It operates through the following segments: B&W Renewable, B&W Environmental, and B&W Thermal. The B&W Renewable segment supports a circular economy, diverting waste from landfills to use for power generation and replacing fossil fuels, while recovering metals and reducing emissions. The B&W Environmental segment focuses on systems for cooling, ash handling, particulate control, nitrogen oxides and sulfur dioxides removal, chemical looping for carbon control, and mercury control. The B&W Thermal segment offers steam generation equipment, aftermarket parts, construction, maintenance, and field services for plants in the power generation, oil and gas, and industrial sectors. The company was founded by George H. Babcock, Stephen Wilcox, Jr., and Joseph P. Manton in 1856 and is headquartered in Akron, OH.

Babcock & Wilcox Enterprises Inc

Babcock & Wilcox (BW) is trending following notice to proceed on a massive contract to deliver 1.2 gigawatts of power generation capacity for AI data centers, a deal many in the community are calling "transformational" for the company. Investors are actively discussing BW's pivotal role in addressing the rapidly growing power demands of the AI sector and anticipating significant re-rating of its shares.

Okta, Inc. engages in the provision of an identity management platform for enterprises. It operates through the United States and International geographical segments. The firm's products include single sign-on, multi-factor authentication, access gateway, API access management, authentication, adaptive MFA and lifecycle management. The company was founded by Todd McKinnon and J. Frederic Kerrest in 2009 and is headquartered in San Francisco, CA.

Okta Inc - Ordinary Shares - Class A

Okta Inc

Okta is navigating market volatility following its recent earnings beat and raised guidance, which was initially met with skepticism over AI disruption fears but was bolstered by a newly authorized share buyback program. The community is sharply divided between frustration over perceived price manipulation and strong conviction in the company's long-term opportunity in securing AI agents, despite broader sector concerns about new AI tools.

Gemini Space Station, Inc. is a holding company, which offers a mobile and web based crypto asset exchange platform, proprietary wallet infrastructure and custody solutions, over-the-counter trading solutions tailored to institutions and professionals, a digital art auction platform, a proprietary United States dollar backed stablecoin, and a credit card product that offers crypto asset rewards on customer purchases. The company was founded by Tyler Winklevoss and Cameron Winklevoss in 2014 and is headquartered in New York, NY.

Gemini Space Station Inc. - Ordinary Shares- Class A

Gemini Space Station

Gemini's new prediction market is live, supported by its CFTC Designated Contract Market (DCM) license, sparking community excitement as it enters this competitive sector. High short interest and rising borrow rates are simultaneously fueling short squeeze speculation.

Webull Corp. engages in the provision of financial services. It offers trading, wealth management product distribution, market data and information, user community, and investor education. The company was founded by An Quan Wang in 2016 and is headquartered in St. Petersburg, FL.

Webull Corp. - Ordinary Shares - Class A

Webull Corp

With its earnings report highly anticipated today, Webull Corp ($BULL) is a hot topic among investors, who are sharply divided between expectations of a significant beat driven by growth initiatives and crypto exposure, and deep-seated frustration over persistent underperformance and alleged market manipulation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Is Trending Stock Novavax, Inc. (NVAX) a Buy Now?

Novavax (NVAX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Novavax (NASDAQ:NVAX) Upgraded by Wall Street Zen to Hold Rating

Wall Street Zen raised shares of Novavax from a "sell" rating to a "hold" rating in a research note on Saturday...

Novavax (NASDAQ:NVAX) Trading Down 9.8% - Here's What Happened

Novavax (NASDAQ:NVAX) Stock Price Down 9.8% - Time to Sell...

Novavax Stock Gains as Q4 Earnings & Sales Beat Estimates

NVAX stock jumps 17% after Q4 swings to a surprise profit on strong licensing revenues and lower costs, with sales soaring 67% year over year.

Company News for Feb 27, 2026

Companies In The Article Are:NVAX,SJM,SHAK,ACMR

<ul class="summary-bullets"><li>The company highlighted Sanofi’s flu-COVID combination shot as a key long-term driver.</li><li>Q4 revenue rose 67% to $147 million, while full-year revenue climbed 65% to $1.12 billion.</li><li>Internal pipeline programs targeting C. difficile, shingles and RSV combinations are advancing, with at least one candidate potentially entering clinical trials by 2027.</li></ul>Shares of Novavax, Inc. (NVAX) hit a more than one-year high on Thursday as investors turned their focus to future growth beyond standalone COVID vaccines, led by its partnership strategy and Sanofi’s flu-COVID combination shot.<a href="https://stocktwits.com/symbol/NVAX">NVAX stock</a> jumped over 17% on Thursday, but slipped 1.3% in extended trading.<h2 class="st-heading-2">Novavax Bets On Combo Vaccines</h2>During its fourth-quarter (Q4) earnings call, the biotech company said it has moved away from its earlier structure centered on standalone COVID vaccine commercialization and is now focused on expanding its pipeline through partnership-led growth.“We have evolved Novavax from a vertically integrated global commercial organization with a singular focus on COVID to a company that is focused on driving both near and long-term value with our proven technology platform via partnering and R&amp;D,” CEO John Jacobs said on the call.A key pillar of the strategy is Sanofi’s development of combination vaccines that pair its flu products with Novavax’s COVID-19 vaccine, Nuvaxovid. The company noted that it would be eligible for a $125 million milestone upon the start of the Phase 3 study for the program.Novavax also pointed to positive early-stage data shared by Sanofi, and added that market research suggests a large share of people who already receive both vaccines would consider switching to a single combination shot.Looking ahead, Novavax expects the 2026-2027 season to mark the first full commercial cycle in which Sanofi markets Nuvaxovid globally. “So yes, the upcoming season looks very promising,” said Elaine O'Hara, chief strategy officer.<h2 class="st-heading-2">Pfizer Matrix Deal Expands Pipeline</h2>In January, the company signed a licensing agreement with Pfizer allowing the use of Matrix-M in two vaccine programs, including one already identified. The company noted that additional material transfer agreements were signed this month, including one with an oncology-focused partner.“We're seeing that once vaccine-focused companies experiment with our adjuvant, they often come back to us to explore more broadly,” the company said. “Our Matrix technology is a cornerstone of our partnering model.”&nbsp;Additionally, early-stage internal vaccine programs targeting C. difficile, shingles and RSV combinations are advancing, with at least one candidate potentially entering clinical testing as early as 2027.The company said that the broader aim is to build a diversified set of recurring revenue streams tied to partnerships and future commercial programs.<h2 class="st-heading-2">NVAX Q4 Review</h2>Novavax reported&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/novavax-swings-to-profit-in-q4-nuvaxovid-revenue/cZTGfprRIbH">Q4 revenue</a> of $147 million, marking a 67% year-on-year increase, and also beating consensus estimates of $90.26 million. Earnings per share (EPS) came in at $0.11, surpassing analyst expectations of $0.55, according to Fiscal AI data.Full-year revenue rose 65% to $1.12 billion, driven largely by $625 million in Nuvaxovid-related sales tied to settlements of earlier advance purchase agreements.Quarterly product sales stood at $39 million, while full-year product sales climbed to $685 million. Revenue recognized under the Sanofi partnership, including milestone and royalty payments, totaled $98 million in Q4 and $386 million for the year. The company said it earned $225 million in milestone payments from the Sanofi collaboration in 2025.&nbsp;Looking ahead, Novavax expects adjusted total revenue of $230 million to $270 million in 2026.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for NVAX was ‘extremely bullish’ amid a 580% surge in 24-hour message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/nvax_ss_png_d2beb88a95.webp" alt="nvax ss.png" width="970" height="144"><figcaption>NVAX sentiment and message volume as of February 27 | Source: Stocktwits</figcaption></figure>One user&nbsp;<a href="https://stocktwits.com/BigCheeze2014/message/646069243">said</a>, “Institutional and Retail FOMO buying will start the squeeze.”<stembedurl>https://stocktwits.com/BigCheeze2014/message/646069243</stembedurl>Another user <a href="https://stocktwits.com/knndy/message/646066793">said</a>, “Friday should see continuing strong Buying pressure coupled with urgent short covering as well.”<stembedurl>https://stocktwits.com/knndy/message/646066793</stembedurl>NVAX stock has jumped 67% year-to-date.For updates and corrections, email newsroom[at]stocktwits[dot]com.

 Ampoules containing the new Corona vaccine Nuvaxovid from the manufacturer Novavax sit on a table at a vaccination center. Photo: Matthias Bein/dpa (Photo by Matthias Bein/picture alliance via Getty Images)

Novavax Stock Hits Over 1-Year High: Is Sanofi’s Flu-COVID Shot The Post-Pandemic Growth Driver?

Novavax said it is pivoting toward a partnership-led model, including a licensing deal with Pfizer for its Matrix-M technology.

Equity

Novavax Q4 Earnings Call Highlights

Novavax (NASDAQ:NVAX) executives told investors the company made significant progress in 2025 executing a strategy centered on partnering its Matrix-M adjuvant technology and advancing a smaller...

Novavax (NASDAQ:NVAX) Posts Quarterly Earnings Results, Beats Expectations By $0.77 EPS

Novavax (NASDAQ:NVAX - Get Free Report) posted its quarterly earnings results on Thursday. The biopharmaceutical company reported $0.11 earnings per share (EPS) for the quarter, topping the consensus...

Power Hour Surge: Quantum Breakouts, Biotech Visibility, and Crypto Strategy Running into the Close

As Wall Street heads into the final hour of trading, momentum is clustering around quantum computing, next-gen biomaterials, vaccine platforms, and digital asset strategy plays. Today’s stock market tape is being defined by revenue beats, national infrastructure deployments, major licensing deals, and one headline-grabbing magazine cover that has small-cap traders leaning forward into the bell. $KBLB, $AEHL, $NVAX, $RXT, $BFLY, $INOQ

Novavax to Participate in Upcoming Investor Conferences

Novavax to Participate in Upcoming Investor Conferences Novavax to Participate in Upcoming Investor Conferences PR Newswire GAITHERSBURG, Md., Feb. 26, 2026 GAITHERSBURG, Md., Feb. 26, 2026...

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $AVGO earnings on Wednesday?

Stocktwits

Stocktwits Polls

Novavax Inc

Major shareholder Shah Capital's impending deadline for management action intensifies speculation about a potential proxy fight to address poor stock performance and strategic direction.

Widespread shareholder frustration targets CEO John Jacobs, who is blamed for the stock's underperformance, lack of significant partnerships, and failure to counter short selling.

Hope persists among investors for a potential short squeeze, believing strong positive news could force short sellers to cover their positions, triggering a sharp price increase.

The Serum Institute of India has secured approval to advance its combined COVID-19 and influenza vaccine, utilizing Novavax's Matrix-M adjuvant, to Phase III clinical trials.

Optimism surrounds Novavax's Matrix-M adjuvant technology, with discussions pointing to its broad application potential beyond current vaccines, including in oncology and other infectious diseases.

NVAX
Novavax Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest NVAX News

NVAXNovavax Inc